Naphazoline + Antazoline

Generic Medicine Info
Indications and Dosage
Ocular allergy
Adult: As combination preparation containing naphazoline HCl 0.05% and antazoline phosphate 0.5% : Apply 1-2 drops in the affected eye 4 times daily.
Angle closure glaucoma.
Special Precautions
Glaucoma, hypertension, CV abnormalities, DM, hyperthyroidism, infection, or injury. Pregnancy and lactation. Avoid in infants and young children <6 yr. Rebound congestion may occur with prolonged use or overuse. Medical advice should be sought if there is ocular pain, vision changes, worsening of redness or irritation of the eye or symptoms lasts > 72 hr. Remove contact lens before use.
Adverse Reactions
Blurring of vision, mild stinging and/or irritation, mydriasis and increased or decreased intraocular pressure. When used in high doses in elderly, naphazoline may liberate pigment granules from the iris.
Drug Interactions
Increased pressor effects with maprotiline or TCA. Possibility of severe hypertensive reaction with MAOI.
Description: Naphazoline, an imidazoline derivative sympathomimetic with α-adrenergic activity, produces vasoconstriction. When applied topically to mucous membranes, it reduces swelling and congestion. It is often used in combination with antazoline, an ethylenediamine derivative antihistamine, in ophthalmic preparations. Antazoline may be used as the hydrochloride, phosphate, sulfate or mesilate salts in ophthalmic preprations, usually in a concentration of 0.5%.
Onset: Local vasoconstriction: within 10 minutes
Duration: Local vasoconstriction: 2-6 hr
Store at 20-25°C (68-77°F). Protect from light.
MIMS Class
Other Eye Preparations
Disclaimer: This information is independently developed by MIMS based on Naphazoline + Antazoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in